[ December 11, 2008 ]
“SCYNEXIS believes that this collaborative project approach with DNDi can play an important role in improving the discovery and development of new therapies for neglected diseases,” said SCYNEXIS President & CEO Yves Ribeill. “We are pleased with the progress this alliance has achieved to date and look forward to continuing to apply our expertise in drug discovery and development to identify new drug candidates to treat sleeping sickness.”
[ New Orleans, USA; Paris, France; Geneva, Switzerland – December 9, 2008]
Pivotal Phase III clinical trial results conclusively show that Nifurtimox-Eflornithine Combination Therapy (NECT) is well tolerated and effective against the advanced stage of T. b. gambiense sleeping sickness, a fatal disease that threatens 60 million people in sub-Saharan Africa.
Science [ December 9, 2008 ]
“A One-Two Punch Against Sleeping Sickness”
Click here to download the full article [PDF]
[ December 7-11, 2008 ]
New Orleans, USA
DNDi sponsored a HAT Symposium: “Addressing R&D challenges in making new drugs available for HAT: potential in the pipeline and recent clinical results”, including presentations on HAT platform, NECT, fexinidazole, and DB289.
by Toriizuka Y, Kinoshita E, Kogure N, Kitajima M, Ishiyama A, Otoguro K, Yamada H, Omura S, Takayama H.
Bioorg Med Chem, December 2008
[ Paris, Geneva – June 11, 2008 ]
Today, the Paris-based Institut de Recherche pour le Développement (IRD) and DNDi announced the implementation of scientific cooperation projects for developing treatments against visceral leishmaniasis, Chagas disease, and sleeping sickness.
by Ioset JR.
Current Organic Chemistry, May 2008
New York Times [ January 8, 2008 ]
“Jump-Start on Slow Trek to Treatment for a Disease“
Click here to read the full article
by Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Karunakara U.
Clinical Infectious Diseases, December 2007
[ Geneva, Switzerland – December 12, 2007 ]
The Drugs for Neglected Diseases initiative (DNDi) has received a USD 25.7 million grant from the Bill & Melinda Gates Foundation to research and develop new medicines to treat human African trypanosomiasis (HAT), also known as sleeping sickness, and visceral leishmaniasis (VL).
[Research Triangle Park, USA, and Geneva, Switzerland – November 1, 2007 ]
SCYNEXIS and Drugs for Neglected Diseases initiative (DNDi), have agreed to collaborate on vital drug discovery research and development of affordable and effective therapies for human African trypanosomiasis (also known as sleeping sickness), one of the most devastating diseases in sub-Saharan Africa.
DNDi participated in two symposiums at the ASTMH in Atlanta.
[ September 2006 ]
Over 200 African scientists from 34 countries met in Nairobi, Kenya, 19-23 September at an international conference organised by the Drugs for Neglected Diseases initiative (DNDi), to explore developing greater regional research partnerships to combat the most neglected diseases, such as sleeping sickness, kala azar and malaria.
by Gros L, Castillo-Acosta VM, Jimenez Jimenez C, Sealey-Cardona M, Vargas S, Manuel Estevez A, Yardley V, Rattray L, Croft SL, Ruiz-Perez LM, Urbina JA, Gilbert IH, Gonzalez-Pacanowska D.
Antimicrob Agents Chemother, August 2006
by Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, Hansell EJ, Chiang PK, Wolff B, Guy KR, Williams J, McKerrow JH.
Chem Biol Drug Des, May 2006
by Vicik R, Hoerr V, Glaser M, Schultheis M, Hansell E, McKerrow JH, Holzgrabe U, Caffrey CR, Ponte-Sucre A, Moll H, Stich A, Schirmeister T.
Bioorg Med Chem Lett, May 2006
by Croft SL, Barrett MP, Urbina JA.
Trends Parasitol, November 2005
[ Tokyo , Japan – July 15, 2005 ]
Today, Drugs for Neglected Diseases initiative (DNDi) signed an agreement to conduct a joint research project with the Kitasato Institute in Japan to find a treatment for human African trypanosomiasis (sleeping sickness), a disease that kills tens of thousands in Africa each year.
[ Basel, Switzerland – January 26, 2005 ]
Strengthening Worldwide Research Effort into Drugs to Treat Sleeping Sickness.
by Lorente SO, Rodrigues JC, Jimenez Jimenez C, Joyce-Menekse M, Rodrigues C, Croft SL, Yardley V, de Luca-Fradley K, Ruiz-Perez LM, Urbina J, de Souza W, Gonzalez Pacanowska D, Gilbert IH.
Antimicrob Agents Chemother, August 2004